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ABSTRACT 
 
Objectives: It is thought that the clinical trial benefits of oral non-steroid anti-inflammatory drugs 
(NSAIDs) may relate to flare designs. The aim of this study was to examine the difference in NSAID 
(including COX-2 inhibitors) response in osteoarthritis (OA) trials based on different designs.  
Methods: Systematic review was undertaken of the databases MEDLINE, EMBASE, AMED, 
CINAHL and the Cochrane library to February 2015. Randomised controlled trials assessing pain, 
function and/or stiffness following commencement of NSAIDs in flare and non-flare designs were 
eligible. Trials were assessed using the Cochrane Risk of Bias tool. Meta-analyses were conducted to 
assess the effect sizes of NSAIDs for OA with flare versus non-flare trial designs. 
Results: Fifty-seven studies including 33,263 participants assessing 26 NSAIDs were included. 
Twenty-two (39%) were flare design, 24 (42%) were non-flare designs, 11 (19%) were possible flare 
designs. On meta-analysis, there was no statistically significant difference in effect size of NSAIDs 
versus placebo between flare and non-flare trial designs for absolute pain and function or stiffness at 
immediate (1 week), short (2 to 4 week) or longer (12 to 13 week) follow-up periods (p>0.05). However 
there was a lower effect size for mean change in pain in flare and possible flare trials compared to non-
flare trials at short-term follow-up (0.36 versus 0.69; p=0.05).  
Conclusions:  Contrary to previous understanding, flare trial designs do not result in an increased 
treatment effect for NSAIDs in people with OA compared to non-flare design. Whether flare design 
influences other outcomes such as joint effusion remains unknown. 
Keywords: Randomised Controlled Trial; NSAIDs; Osteoarthritis; Effect Size; Methodology 
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INTRODUCTION 
Osteoarthritis (OA) is a debilitating musculoskeletal disorder which symptomatically affects 
approximately 10% of the population aged over 60 years, and increases with age [1,2]. The most 
commonly affected joints are the hands, feet, knees and hips, with principle manifestations being pain, 
stiffness and resultant loss of function and independence [3]. The optimal treatment for people with OA 
combines both pharmacological and non-pharmacological treatments [4]. Nonsteroidal anti-
inflammatory drugs (NSAIDs and selective cyclooxygenase-2 inhibitors) are the most commonly used 
painkillers for people with OA in Europe and the USA with 20% to 35% of the OA population reporting 
their use [5,6].  
Flare design trials have been commonly used to assess the efficacy of NSAIDs. They are defined as 
trials which have recruited patients with increased pain after ceasing their usual pharmacological 
treatment [7]. Accordingly, these participants may respond differently to the general OA population 
with respect to the therapy under investigation. This may be of particular importance if only those who 
have previously responded to a NSAID are recruited to a trial investigating NSAID efficacy, inflating 
the effect size compared to an unselected OA group.  
Trijau et al [8] previously presented a well-designed meta-analysis comparing the efficacy of NSAIDs 
in flare and non-flare design trials. They reported that flare trials evaluating NSAIDs resulted in a higher 
magnitude of treatment effect compared to non-flare trials. However, a large number of relevant papers 
have been published since the March 2009 search date in that publication. Our aim was therefore to 
conduct a contemporary systematic literature review investigating the effects of flare design trials on 
the efficacy of NSAIDs for people with OA and then to perform a meta-regression to examine the 
effects of other possible factors including study setting, allocation concealment and sample size on 
outcomes.  
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METHODS 
Search Strategy 
A search strategy was undertaken of the published databases: MEDLINE, EMBASE, AMED, CINAHL 
and the Cochrane library. The search was undertaken from database inception to 1st February 2015. A 
review of the potentially included papers’ reference lists and previous review articles was undertaken 
to identify any additional studies. The search terms for the MEDLINE search are presented in 
Supplementary Table 1. These were amended for the other search databases. We did not exclude papers 
based on year or language of publication.  
Identification of Studies 
All randomised placebo controlled trials assessing the efficacy of NSAIDs in people with OA were 
included. Flare design was defined as trials where participants were only eligible when they had 
increased pain after ceasing their usual treatment before entering the trial [7]. Where there was 
uncertainty regarding the magnitude of this increased pain but there was sufficient evidence to suggest 
that these could have been flare design trials, the studies were included and termed ‘possible flare design’ 
trials. Where there was no reference to ‘flare trial design’ and it was clear a non-flare trial design was 
adopted, these were defined as ‘non-flare design’ trials. Participants with OA of any joint or multiple 
joints were included. OA was defined according to the American College of Rheumatology (ACR) 
criteria, radiological and/or clinical diagnosis [9]. The interventions included all NSAIDs (conventional 
and COX-2 inhibitors).   
Outcomes 
The primary outcome was pain. Pain could be measured by visual analogue scale (VAS) or numerical 
rating scale (NRS) methods, or as a sub-domain of an overall scoring system such as the Western 
Ontario and McMaster Universities Arthritis Index (WOMAC)[10]. Where pain was assessed using a 
number of different measures, we selected the scale according to the hierarchy of the outcomes 
suggested by Juhl et al [11]. Secondary outcome measures were function and stiffness. 
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Outcomes were assessed at specific follow-up periods. These were classified a priori as: immediate, 
short or longer-term. Immediate term outcomes were defined as outcomes within the first week of 
commencing the trial; short term was defined as two to four weeks following commencement, and 
longer-term outcomes were defined as six weeks and over. 
Data Extraction 
Data were extracted by one reviewer (KZ) and validated by three others (NA, XC, TS). Any 
disagreements were resolved through discussion with a fifth reviewer (WZ). Data were extracted onto 
a pre-defined database and included: country of origin, sample size, gender, age, BMI, setting 
(community or hospital-based), NSAID medication (type, dose, frequency, duration, route of delivery), 
placebo comparison, follow-up intervals and period, baseline and follow-up outcomes.    
Critical Appraisal 
Each included trial was assessed for methodological quality using the Cochrane Risk of Bias tool [12]. 
Trial design was assessed using the five criteria: random sequence generation, allocation concealment, 
blinding to participants, blinding to outcome assessment, withdrawals (attrition bias) and selective 
reporting (reporting bias).  
Statistical Methods  
Study heterogeneity was assessed through visual assessment of the participant characteristics, trial 
design, NSAIDs and placebo approaches and outcome measures. Where there was evidence of trial 
homogeneity, a meta-analysis was undertaken.  
Heterogeneity was measured using I2 index and Chi-squared test. Where I2 was 30% or above and Chi-
squared p ≤ 0.10, a random-effects meta-analysis was undertaken. When I2 was less than 30% and Chi-
squared p > 0.10, a fixed effects meta-analysis was undertaken. All meta-analyses were undertaken by 
two reviewers (TS, KZ) and interpreted by four reviewers. Through this we assessed the effect size (ES) 
(standard mean difference between NSAID versus placebo interventions) overall and at each time point 
(immediate, short, longer-term). Clinically, an effect size of 0.2 suggested a small effect, 0.5 meant a 
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moderate effect and 0.8 and over indicated a large effect.  The analysis of flare versus non-flare trial 
design was then made to assess for differences between these two subgroups of the NSAID data, 
presenting this with Chi-square p-values and I² statistics between the two pooled effect sizes. A 
sensitivity analysis was also undertaken to compare ‘flare design’ or ‘possible flare designs’ for each 
time point.  
A meta-regression analysis (random-effects model) was undertaken to confirm whether flare design 
affected pain and other clinical outcomes given the adjustment for setting (community-based), 
allocation concealment, intention-to-treat analysis and whether there was more than or less than 100 
participants per study arm, as suggested by Nüesch et al [13]. These are the common factors that may 
affect the results from RCTs and that may confound the difference between flare and non-flare designs. 
The partial regression coefficient (β) was used to present the contribution of each variable. A funnel 
plot was constructed to assess for publication bias [14].  
All data were presented with 95% confidence intervals (CI) and with forest-plots. A two-sided p-value 
of < 0.05 was considered statistically significant. Analyses were undertaken using RevMan (Review 
Manager). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011) 
and STATA (version 14.0, STATA Corp, Dallas, Texas, USA).   
 
RESULTS 
Characteristics of included studies 
A total of 8,592 citations were identified from the search. Of these 57 were eligible and included in the 
meta-analysis (Supplementary Figure 1). Of the 57 trials, 22 (39%) were ‘flare designs’, 24 (42%) were 
‘non-flare designs’ and 11 (19%) were ‘possible flare designs’ (Supplementary Tables 2 and 3). Of the 
22 flare designs, 20 (91%) were funded by industry and two were unclear about funding source. In the 
24 non-flare trial designs, 10 (42%) were funded by industry, two were funded by public funding (8%), 
and 13 remained unclear about funding source.  
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A total of 33,263 participants were included in the review (10,480 men/21,877 women). Two studies 
did not provide the gender composition of their cohort [15,16]. Mean age ranged from 53.5 [17] to 83 
years [18]. The duration of NSAID/placebo intervention ranged from one week [19,20] to 26 weeks 
[21]. Thirty studies were for knee OA, four for hip OA, 21 for hip and knee OA, and two for hand OA. 
The mean duration of OA was documented in 31 papers. This ranged from 2.2 years [22] to 15 years 
[18]. Trials were conducted in a hospital setting in 36 studies, in the community in two studies, whilst 
unclear in 19 papers.  
Critical Appraisal 
In general, the quality of studies was higher in the flare designs than the non-flare or possible flare 
design trials (Supplementary Table 4). There was a higher proportion of papers which clearly designed 
the randomisation, blinded of their assessors, and assessed a minimum of 85% of their cohort in the 
flare compared to non/possible flare trials. The quality of studies was comparable between the non-flare 
and possible flare trials.  
Publication Bias 
As presented in Supplementary Figure 2 there was some evidence of small sample size publication bias 
in the non-flare designs but not in flare designs. That is, studies with smaller sample size were more 
likely to produce larger effect size and they were more likely to be published in non-flare trials. 
Primary outcome: Pain 
There was no statistically significant difference in effect size between flare and non-flare trial design 
for pain as measured by mean change in pain score (p=0.08; I2=66.4%; Figure 1; Table 1) or absolute 
pain score (p=0.23; I2=29.4%; Figure 2) These findings remained when the data were analysed by 
follow-up period for the flare versus non-flare trials (Table 2). There were two exceptions to this. There 
was a lower effect size in flare and possible flare trial designs in mean change in pain score at short-
term follow-up compared to non-flare trial designs (ES: 0.36 vs. 0.69; p=0.05; I2=73.3%; Table 3), 
although this presented with high statistical heterogeneity. Conversely there was a statistically 
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significant difference between flare and possible flare trials for absolute pain score at longer-term 
follow-up, being greater in flare trial designs (ES: 0.85 vs. 0.40; p=0.05; I2=74.0%), and in the flare and 
non-flare trials for the same outcome at the same follow-up period (ES: 0.44 vs. 0.00; p<0.01; I2=90.2%).  
Secondary outcomes: Function 
There was no statistically significant difference in effect size between flare and non-flare trial design 
for function as measured by mean change (p=0.54; I2=0%; Table 1) or absolute functional scores 
(p=0.08; I2=67.4%). However, when assessed by follow-up period, there was a statistical difference for 
immediate-term follow-up analysis with greater effect sizes in mean change in functional scores for 
non-flare trial designs compared to flare trial papers (ES: 0.26 vs. 0.47; p=0.04; I2=75.6%; Table 2). 
This was also evident for the short-term follow-up in the flare and possible flare trial designs versus 
non-flare trial designs (ES: 0.28 vs. 0.68; p<0.01; I2=93.5%; Table 3), and in the longer-term follow-up 
(ES: 0.35 vs. 0.55; p=0.01; I2=84.9%; Table 3). There was no statistically significant difference between 
flare versus non-flare (Table 2) and flare/possible flare trial designs versus non-flare trial design for 
absolute functional score (Table 3).  
Secondary outcomes: Stiffness 
There was no statistically significant difference in effect size between flare and non-flare trial design 
for stiffness as measured with mean change in functional scores (p=0.75; I2=0%; Table 1) or absolute 
stiffness scores (p=1.00; I2=0%). There was no statistically significant difference in effect size between 
flare and non-flare or flare and possible flare compared to non-flare trial designs for stiffness as 
measured with mean change from baseline to any follow-up interval or absolute score (Table 2; Table 
3). The only exception was for non-flare trial designs which demonstrated a greater effect size for 
absolute stiffness score compared to flare and possible flare trial designs on immediate-term follow-up 
analysis (ES: 0.22 vs. 0.84; p=0.01; I2=86.3%; Table 3). 
 
Meta-Regression 
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The results of the meta-regression are presented in Table 4. This analysis confirmed that flare design 
had similar results as non-flare designs, given the adjustment for the five major study-level confounding 
factors (study setting, allocation concealment, ITT, blinding to participants and ≥100 participants per 
trial arm).  
 
DISCUSSION 
The findings of this paper indicate that there is no significant difference between flare and non-flare 
trial designs for NSAIDs versus placebo when assessed in people with OA. Mean change in pain at 
short-term follow-up was significantly higher in non-flare than flare and possible flare trial designs. 
These results differ to previous findings [8]. The current study included an increased number of trials: 
whilst the earlier paper assessed 33 studies, all of which were included in the current analysis, an 
additional 24 trials contributed to our analysis. Furthermore, we conducted a meta-regression analysis 
to adjust for other variables that may have influenced the outcome and confirmed that the flare design 
had indeed no impact on results. Both our analysis and Trijiau et al’s [8] adopted a similar definition of 
flare trial design; hence this was not a potential source of difference between the analyses. Similarly, 
the new trials included since Trijau et al’s [8] meta-analysis did not differ in terms of duration, patient 
numbers or characteristics. 
Previous studies have suggested that flare study designs may be a more efficient trial design when 
investigating NSAIDs in people with OA [7,8]. This has been justified through reported higher 
treatment effect conferred through flare designs. It was suggested that flare trial design may be valuable 
to assess the efficacy of a NSAID without the additional effects of other analgesics (current or recently 
previous) affecting outcome, to provide higher discriminant capacity, thus allowing sufficiently 
powerful analyses from smaller sample sizes [8]. Accordingly, such NSAIDs may be more likely to 
provide change in pain scores ranging from 30% to 70% which is the most sensitive change on the “S” 
curve of pain response. However, the current results question the value of the flare design.   
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The statistical analysis indicated small sample size publication bias, especially for non-flare designs, 
which tended to have smaller sample size, therefore more likely to produce larger effect sizes 
(Supplementary Figure 2). This may partially explain the reason why non-flare designs had larger pain 
reduction than flare designs in the short-term. Should this publication bias be excluded, it is likely that 
flare and non-flare designs have no difference in the short-term. 
One explanation for trials which found a difference between flare and non-flare trial design may be 
attributed to recruitment or trial selection bias. Consideration should be given to whether flare trial 
designs recruit a certain phenotype of patient. It may be that flare trial designs recruit NSAID responders 
with a more ‘inflammatory’ phenotype of OA. In such instances, these participants, when ceasing their 
usual medications, and particularly NSAIDs, would be recruited as their pain could flare within the 
specified wash-out period. Conversely, those with more mechanically-related OA pain may not have 
the same change in pain scores on discontinuing NSAIDs, and therefore be excluded. However, they 
may also increase the chances of detecting a ‘regression to the mean’ as even if no treatment is provided, 
pain which has ‘flared up’ could naturally subside. This may therefore be considered a substantial 
limitation to this study design. 
A second possible explanation for our findings is that participants whose pain increases following 
cessation of current analgesia may gain more pain relief not just from their NSAID but also from the 
placebo intervention.  This is conceivable since participants in both trial arms in the flare study design 
might have an increased expectancy, a major driver of placebo/contextual response [23] through 
previous experience of the positive effects from their medications. Consequently there would be no 
difference between the two trial arms for flare-trials, i.e. no inflation of effect size calculated on the 
separation of treatment from the placebo intervention, compared to the difference between treatment 
and placebo arms in non-flare trials.   
The included papers poorly documented the frequency to which their participants presented with joint 
effusion, or how the presence of effusion changed with stopping treatment. Maricar et al [24] found 
mixed results about whether clinically-detected joint effusion is a significant predictor of pain outcome 
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following intra-articular steroid injection in people with knee OA. Modern imaging studies suggest 
clinical detection of synovitis at the knee is not very accurate [25], and since synovitis is extremely 
common in knee OA [25] (the most prevalent joint in this analysis), it is very likely that most 
participants in the included studies had synovitis, though of varying degree. The accurate detection of 
synovitis volume or activity may in future identify a responsive subgroup to anti-inflammatory therapy 
within the OA population [26]. 
There are limitations to this work which should be considered when interpreting these findings. Firstly, 
the analysis was based on study-level analysis. Accordingly it was not possible to account for potential 
variation between patients at an individual patient data level. Secondly, whilst we adopted a clear 
definition of flare design based on current recommendations [7], the exact nature of the trial design was 
unclear in 11 papers (19%). To adjust for this potential classification-based uncertainty, we analysed 
‘possible flare designs’ separately in a sensitivity analysis, which did not change the overall findings. 
Thirdly data in this analysis were only based on NSAIDs. It is therefore not possible to generalise these 
findings to other analgesics, which may have a different response to pain and inflammatory components 
to specific patient’s presenting OA. Fourthly the included trials did not state which medications their 
participants stopped at study entry, that is, whether they stopped NSAIDs or other analgesics. If the 
majority of participants stopped NSAIDs, the implication is that stopping NSAID response predicts 
NSAID response in flare trials. This possibility is supported by a recent European survey suggesting 
that NSAIDs are used in nearly 60% of the OA population [5]. However, conversely a large proportion 
of participants (40%) would have stopped other analgesics. This subgroup may therefore have not been 
eligible for flare-trials, thereby potentially accounting for a difference between flare/non-flare trials. 
Limited information on which medications were ceased on study entry, precludes this analysis. Finally, 
the analyses were based on randomised controlled trial cohorts, and therefore homogenous, self-
selecting populations. This loses diversity of the wider, general public, which may reduce the clinical 
sensitivity and generalisability to answer the research question. 
To conclude, the results from this meta-analysis suggest there is no statistically significant difference 
in effect size in pain, function or stiffness for flare compared to non-flare trials in the assessment of 
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NSAID efficacy for people with OA, with some evidence indicating an increase in treatment effect 
detected in non-flare trial designs. Consideration should be made by industrial and non-industrial 
researchers on their rationale for using flare trial design, based on these results. 
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Figure 1: Forest plot of mean change in pain score for NSAID versus Placebo for flare versus non-
flare trial design. 
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Figure 2: Forest plot of absolute pain score for NSAID versus Placebo for flare versus non-flare trial 
design. 
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Figure 2: Forest plot of absolute pain score for NSAID versus Placebo for flare versus non-flare trial 
design. 
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Table 1: Flare versus non-flare trial design meta-analysis results by outcome measure. 
Outcome N Flare Trial Design N Non-Flare Trial Design Difference 
between flare  
and non-flare 
(Chi²; I2) 
Effect size; 95% CI Statistical 
Heterogeneity (Chi2 
P-value/I2%) 
Effect size; 95% CI Statistical 
Heterogeneity (Chi2 P-
value/I2%) 
Absolute Pain 13 -0.42 [-0.52, -0.32] P = 0.008; I² = 56% 
 
24 -0.53 [-0.69, -0.37] P < 0.00001; I² = 81% P = 0.23; I² = 
29.4% 
Mean change in pain score 48 -0.43 [-0.48, -0.38] 
 
P < 0.00001; I² = 59% 
 
37 -0.56 [-0.71, -0.42] P < 0.00001; I² = 94% P = 0.08; I² = 
66.4% 
Absolute functional score 10 -0.40 [-0.47, -0.33] 
 
P = 0.28; I² = 18% 
 
8 -0.13 [-0.43, 0.18] P < 0.00001; I² = 85% 
 
P = 0.08; I² = 
67.4% 
Mean change in functional 
score 
38 -0.51 [-0.61, -0.41] P < 0.00001; I² = 87% 
 
39 -0.58 [-0.67, -0.48] P < 0.00001; I² = 86% P = 0.34; I² = 
0% 
Absolute stiffness score 2 -0.48 [-0.67, -0.30] P = 0.23; I² = 31% 
 
7 -0.49 [-0.66, -0.31] P = 0.22; I² = 27% 
 
P = 1.00; I² = 
0% 
Mean change in stiffness 
score 
27 -0.38 [-0.44, -0.31] P = 0.0005; I² = 54% 
 
16 -0.35 [-0.50, -0.20] P < 0.00001; I² = 84% P = 0.75; I² = 
0% 
CI – confidence intervals; I2 – inconsistency value; vs. - versus 
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Table 2: Flare versus non-flare trial design meta-analysis results as assessed by immediate, short, and longer-term follow-up intervals. 
Outcome Follow-
up 
interval 
(weeks) 
N Flare Trial Design N Non-Flare Trial Design Difference 
between flare and 
non-flare (Chi²; I2) Effect size [95% CI] Statistical 
Heterogeneity 
(Chi2 P-value/I2%) 
Effect size [95% 
CI] 
Statistical 
Heterogeneity (Chi2 
P-value/I2%) 
Absolute Pain 0 - 1  0 N/E N/E 8 -0.56 [-0.82, -0.31] P < 0.0001; 78% N/E 
2 – 4 4 -0.36 [-0.59, -0.13] P = 0.01; 72% 15 -0.55 [-0.77, -0.34] P < 0.00001; 82% P = 0.24; 28.9% 
6 - over 9 -0.44 [-0.55, -0.34] P = 0.06; 47% 2 -0.15 [-0.48, 0.18] P = 0.11; 60% P = 0.10; 62.1% 
Mean change in 
pain score 
0 - 1  4 -0.35 [-0.48, -0.23] P = 0.31; 16% 0 N/E N/E N/E 
2 – 4 8 -0.44 [-0.50, -0.37] P = 0.97; 0% 14 -0.69 [-1.01, -0.37] P < 0.00001; 97% P = 0.13; 56.5% 
6 - over 35 -0.44 [-0.51, -0.37] P < 0.00001; 68% 23 -0.47 [-0.60, -0.34] P < 0.00001; 88% P = 0.71; 0.0% 
Absolute 
functional score 
0 - 1  0 N/E N/E 2 0.77 [-1.25, 2.79] P < 0.00001; 96% N/E 
2 – 4 2 -0.34 [-0.47, -0.21] P = 0.76; 0% 6 -0.32 [-0.54, -0.10] P = 0.01; 67% P = 0.85; 0.0% 
6 - over 8 -0.43 [-0.51, -0.34] P = 0.20; 28% 0 N/E N/E N/E 
Mean change in 
functional score 
0 - 1  4 -0.26 [-0.38, -0.15] P = 0.59; 0% 3 -0.47 [-0.64, -0.31] P = 0.40; 0% P = 0.04; 75.6%* 
2 – 4 7 -0.86 [-1.29, -0.42] P < 0.00001; 97% 14 -0.68 [-0.85, -0.50] P < 0.00001; 87% P = 0.45; 0.0% 
6 - over 27 -0.46 [-0.52, -0.39] P = 0.0003; 56% 22 -0.55 [-0.68, -0.42] P < 0.0001; 86% P = 0.23; 31.4% 
Absolute 
stiffness score 
0 - 1  0 N/E N/E 1 -0.84 [-1.50, -0.18] P = 0.01; N/E N/E 
2 – 4 0 N/E N/E 6 -0.46 [-0.63, -0.29] P = 0.23; 27% N/E 
6 - over 2 -0.48 [-0.67, -0.30] P = 0.23; 31% 0 N/E N/E N/E 
Mean change in 
stiffness score 
0 - 1  0 N/E N/E 0 N/E N/E N/E 
2 – 4 7 -0.31 [-0.38, -0.24] P = 0.94; 0% 4 -0.11 [-0.42, 0.20] P < 0.0001; 86% P = 0.21; 37.2% 
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6 - over 20 -0.41 [-0.50, -0.32] P < 0.0001; 64% 12 -0.43 [-0.61, -0.26] P < 0.0001; 83% P = 0.81; 0.0% 
* - signified analysis reach a statistical significant difference; CI – confidence intervals; I2 – inconsistency value; N – number of studies; N/E – Not 
estimatable; vs. - versus 
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Table 3: Flare and possible flare versus non-flare trial design meta-analysis results as assessed by immediate, short and longer-term follow-up intervals. 
Outcome Follow-up 
interval 
(weeks) 
N Flare and Possible Flare Trial Design N Not Flare Trial Design Difference between 
flare  and possible 
flare to non-flare 
(Chi²; I2) 
 Effect size [95% CI] Statistical 
Heterogeneity 
(Chi2 P-value/I2%) 
 Effect size [95% 
CI] 
Statistical 
Heterogeneity (Chi2 
P-value/I2%) 
Absolute Pain 0 - 1  2 -0.25 [-1.21, 0.70] P = 0.004; 88% 8 -0.56 [-0.82, -0.31] P < 0.0001; 78% P = 0.54; 0% 
2 – 4 11 -0.39 [-0.59, -0.20] P < 0.0001; 75% 15 -0.55 [-0.77, -0.34] P < 0.00001; 82% P = 0.28; 14.4% 
6 - over 6 -0.85 [-1.15, -0.55] P < 0.00001; 97% 2 -0.40 [-0.74, -0.06] P = 0.91; 0% P = 0.05; 74.6%* 
Mean change in 
pain score 
0 - 1  1 -0.52 [-0.99, -0.05] P = 0.03; N/E 0 N/E N/E N/E 
2 – 4 8 -0.36 [-0.46, -0.26] P = 0.11; 41% 14 -0.69 [-1.01, -0.37] P < 0.00001; 97% P = 0.05; 73.3%* 
6 - over 20 -0.34 [-0.40, -0.27] P = 0.02; 44% 23 -0.47 [-0.60, -0.33] P < 0.00001; 89% P = 0.08; 67.5% 
Absolute 
functional score 
0 - 1  1 0.20 [-0.20, 0.61] P = 0.32 2 0.77 [-1.25, 2.79] P < 0.00001; 96% P = 0.59; 0% 
2 – 4 5 -0.30 [-0.55, -0.06] P = 0.06; 56% 6 -0.32 [-0.54, -0.10] P = 0.01; 67% P = 0.95; 0% 
6 – over 5 -0.28 [-0.57, 0.00] P = 0.02; 65% 0 N/E N/E N/E 
Mean change in 
functional score 
0 - 1  0 N/E N/E 3 -0.47 [-0.64, -0.31] P = 0.40; 0% N/E 
2 – 4 4 -0.28 [-0.38, -0.19] P = 0.49; 0% 14 -0.68 [-0.85, -0.50] P < 0.00001; 87% P < 0.01; 93.5%* 
6 - over 16 -0.35 [-0.42, -0.28] P = 0.01; 50% 22 -0.55 [-0.68, -0.42] P < 0.00001; 86% P = 0.01; 84.9%* 
Absolute 
stiffness score 
0 - 1  1 0.22 [-0.18, 0.62] P = 0.28 1 -0.84 [-1.50, -0.18] P = 0.01 P = 0.01; 86.3%* 
2 – 4 4 -0.61 [-1.47, 0.25] P < 0.0001; 87% 6 -0.46 [-0.63, -0.29] P = 0.23; 27% P = 0.74; 0% 
6 - over 0 N/E N/E 0 N/E N/E N/E 
Mean change in 
stiffness score 
0 - 1  0 N/E N/E 0 N/E N/E N/E 
2 – 4 7 -0.31 [-0.38, -0.24] P = 0.94; 0% 4 -0.11 [-0.42, 0.20] P < 0.0001; 86% P = 0.21; 37.2% 
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6 - over 8 -0.61 [-0.74, -0.48] P < 0.00001; 84% 12 -0.59 [-0.73, -0.45] P < 0.00001; 89%  P = 0.83; 0% 
* - signified analysis reach a statistical significant difference; CI – confidence intervals; I2 – inconsistency value; N/E – Not estimatable; vs. - versus 
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Table 4: Meta-regression of effect size of NSAIDs for osteoarthritis pain (number of observation=125) 
 
 Β (95% Confidence Intervals) P-value 
Flare design (yes=1, all others=0) 0.033 (-0.184, 0.251 0.763  
Setting (community yes=1, all others=0) 0.324 (-0.154, 0.802) 0.182  
Allocation concealment (yes=1, all others=0) -0.030  (-0.260, 0.200) 0.798 
Blinding to participants (yes=1, all others=0) -0.056 (-0.704, 0.592) 0.864 
Intent to treat analysis (yes=1, no=0) 0.076  (-0.167, 0.319) 0.538 
Sample size (>=100 per arm vs. <100 per arm) 0.205 (-0.015, 0.424) 0.067 
_cons -0.617 (-1.238, 0.004) 0.051 
β – meta-regression value;  p-value – probability value
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Supplementary Figure 1: PRISMA flow-chart 
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Supplementary Figure 2: Funnel plot assessing small sample size publication bias for primary 
outcome measure (mean change in pain score) for flare versus non-flare trial design. 
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Supplementary Table 1: MEDLINE search strategy 
  
1. osteoarthritis.mp. or exp osteoarthritis/ 
2. arthrosis.mp. 
3. osteoarthr$.mp. 
4. (degenerative adj2 arthritis).mp. 
5. gonarthrosis.mp. 
6. coxarthrosis.mp. 
7. or/1-6 
8. randomized controlled trial.pt. 
9. controlled clinical trial.pt. 
10. randomized.ab. 
11. placebo.ab. 
12. clinical trials as topic.sh. 
13. randomly.ab. 
14. trial.ti. 
15. or/8-14 
16. (animals not (humans and animals)).sh. 
17. 15 not 16 
18. exp Anti-Inflammatory Agents, Non-Steroidal/ 164 
19. NSAIDs.mp. 
20. cyclooxygenase.mp. 
21. cox* inhibitor.mp. 
22. *coxib/ 
23. Lodine.mp. 
24. celecoxib.mp. 
25. Celebrex.mp. 
26. rofecoxib.mp. 
27. Vioxx.mp. 
28. meloxicam.mp. 
29. Mobic.mp. 
30. *Naprosyn/ 
31. Anaprox*.mp. 
32. Naprapac Aleve.mp. 
33. (Cataflam or Voltaren or Arthrotec or Pennsaid).mp. 
34. lumiracoxib.mp. 
35. etoricoxib.mp. 
36. Motrin.mp. 
37. Profen.mp. 
38. Vicoprofen.mp. 
39. Combunox.mp. 
40. Advil.mp. 
41. Dolobid.mp. 
42. Nalfon.mp. 
43. Ansaid.mp. 
44. indometacin.mp. 
45. Indocin.mp. 
46. Indo-Lemmon.mp. 
47. Indomethagan.mp. 
48. Oruvail.mp. 
49. Toradol.mp. 
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Supplementary Table 1: MEDLINE search strategy (cont) 
 
 
 
 
 
 
 
 
50. Mefenamic Acid.mp. or exp Mefenamic Acid/  
51. Ponstel.mp.  
52. Nabumetone.mp.  
53. Relafen.mp.  
54. Oxaprozin.mp.  
55. Daypro.mp.  
56. Piroxicam.mp. or exp Piroxicam/  
57. Feldene.mp.  
58. Sulindac.mp. or exp Sulindac/  
59. Clinoril.mp.  
60. Tolmetin.mp. or exp Tolmetin/  
61. Tolectin.mp.  
62. Valdecoxib.mp. 
63. Bextra.mp.  
64. Diacerein.mp.  
65. Diacerhein.mp.  
66. Rhein.mp.  
67. Anthraquinones.mp. or exp Anthraquinones/  
68. Diacetyilrhein.mp.  
69. ART 50.mp.  
70. Cyclooxygenase Inhibitors.mp. or exp Cyclooxygenase Inhibitors/  
71. exp Cyclooxygenase Inhibitors/ or exp Cyclooxygenase 2 Inhibitors/  
72. exp Aspirin/ or Aspirin.mp.  
73. Etodolac.mp. or exp Etodolac/  
74. naproxen.mp. or exp Naproxen/  
75. Diclofenac.mp. or exp Diclofenac/  
76. Ibuprofen.mp. or exp Ibuprofen/  
77. Diflunisal.mp. or exp Diflunisal/  
78. Fenoprofen.mp. or exp Fenoprofen/  
79. Flurbiprofen.mp. or exp Flurbiprofen/  
80. Indomethacin.mp. or exp Indomethacin/  
81. Ketoprofen.mp. or exp Ketoprofen/  
82. exp Ketorolac/ or Ketorolac.mp.  
83. or/18-82 
84. and/7,17,83 
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Supplementary Table 2: Study Characteristics (Study design) 
Study Funding 
(Public/ 
Industry/ 
Unclear) 
Washout 
period 
specified 
Flare Design 
Clearly 
Stated 
Definition of Flare Design 
Altman [21] Unclear  X No information provided. 
Baerwald [45] Industry   To be eligible for inclusion, patients had to have experienced a flare of pain at the baseline visit (defined as a 
score of 50 mm for question 1 of the WOMAC pain subscale [17] that was increased by 15 mm as compared 
with the screening visit).” 
Bensen [19] Industry   OA was considered symptom-active if the patient's and physician's global assessment scores were "fair," "poor," 
or "very poor" and if 3 of the following 4 criteria were present: (1) a patient's assessment of arthritis pain (VAS) 
measurement of 40 mm or higher, (2) an increase of 2 points or more in the OA Severity Index from the 
screening assessment; (3) an increase from the screening visit of 1 grade or more in the patient's global 
assessment; and (4) an increase from the screening visit of 1 grade or more in the physician's global assessment. 
For patients not receiving NSAID or analgesic therapy and who had uncontrolled OA, 3 of the following 4 
conditions were necessary for randomization at the baseline visit: (1) a patient's assessment of arthritis pain 
(VAS) measurement of 40 mm or higher, (2) an OA Severity Index score of 7 or more; (3) a patient's global 
assessment grade of poor or very poor, and (4) a physician's global assessment grade of poor or very poor 
Biegert [65] Public  X No information provided. 
Bingham [38] Industry   NSAID users had to demonstrate a minimum score of 40mm with an increase of 15mm on patient-assessed pain 
walking on a flat surface, and Eligibility required patients to meet specific flare criteria upon medication 
washout. IGADS worsening of at least one point on a 5-point Likert scale. Acetaminophen users had to 
demonstrate a minimum of 40mm of patient-assessed pain walking on a flat surface, fair, poor or very poor on 
IGADS, and a minimum of 40mm on PGADS. 
Bocanegra [28] Industry   Worsening of the OA symptoms was defined as at least 2 of the following 3: (1) an increase of one grade or 
more since screening, or a score of "poor" or "very poor," on the physician's Global Assessment"; (2) an increase 
of at least one grade since screening, or a score of "poor" or "very poor," on the patient's Global Assessment"; 
and (3) an increase of at least 2 points since screening, or a score of 7 or higher, on the Osteoarthritis Severity 
Index 
Bourgeois [16] Unclear  X No information provided. 
Case [63] Public  X No information provided. 
Cryer [46] Industry   Patients had a wash-out period of 7-14 days, a baseline visit (following a flare in OA pain) 
Davies [56] Industry  Possible No information provided. 
Day [30] Industry   patients were randomized to the study if they reported a minimum of 40mm and an increase of 15 mm on the 
VAS compared with the value at the screening visit 
DeLemos [75] Industry  X No information provided. 
Dickson [60] Industry  X No information provided. 
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Ding [74] Public Unclear Possible No information provided. 
Dougados [72] Industry  X No information provided. 
Dreiser [52] Unclear  X No information provided. 
Ehrich [29] Industry   Patients were randomized to the study if they reported a minimum of 40 mm on a 100 mm OA pain VASVAS (0 
mm = no pain; 100 mm = extreme pain) after discontinuation of NSAID therapy, and an increase of 15 mm 
compared with the value recorded at the screening visit 
Ehrich [31] Unclear   To be eligible, patients had to demonstrate worsening in pain after discontinuation of previous therapy with 
NSAIDs 
El-Mehairy [49] Unclear  X No information provided. 
Essex [48] Industry   African American patients aged ≥ 45 years, with OA of the knee (diagnosed according to 
American College of Rheumatology guidelines30) in a flare state, and with a functional capacity classification of 
I – III were eligible for study participation.” 
“For patients receiving NSAID or analgesic therapy, a flare was demonstrated if the physician’s Global 
Assessment of Arthritis and the patient’s Global Assessment of Arthritis were both ‘fair’, ‘poor’ or ‘very poor’ at 
the baseline visit, and if the baseline Patient’s Assessment of Arthritis Pain VAS measurement was between 40 
and 90 mm (out of 100 mm; 0 representing no pain and 100 representing very severe pain), the patient’s Global 
Assessment of Arthritis showed an increase of one or more grades and the physician’s Global Assessment of 
Arthritis showed an increase of one or more grades.” 
“For patients who were not receiving treatment, a flare was defined if the Patient’s Assessment of Arthritis Pain 
VAS was between 40 and 90 mm, the patient’s and physician’s Global Assessment of Arthritis was ‘poor’ or 
‘very poor’, and the Global Assessment of Arthritis was ‘poor’ or ‘very poor’ 
Fleischmann [36] Industry   At the end of the screening period, patients with pain intensity (during the last 24 hours) in the targeted 
knee >=40 mm on a 100 mm VAS were eligible for entry into the treatment phase 
Gibofsky [64] Industry X X No information provided. 
Goldstein [58] Unclear Unclear Possible No information provided. 
Grifka [35] Industry   Patients were required to have pain intensity a 40 mm on a 100 mm VAS(most pain) in the target hand during 
the 24 hours prior to baseline. An increase in pain intensity in the target hand of either a 20% or a 10 mm VAS at 
the baseline visit com-pared with screening values (whichever was greater) was required to assess those patients 
who required analgesia 
Haghighi [68] Unclear  X No information provided. 
Karlsson [43] Industry   Patients were also required to experience a pain flare within 3–14 days of discontinuing all pain medications 
during a washout phase (between screening and baseline). The VAS pain score for pain on walking on a flat 
surface at baseline was required to be ≥ 40 mm, with an increase of at least 15 mm compared to screening 
Kivitz [62] Industry  Possible No information provided. 
Kruger [73] Unclear  X No information provided. 
Lee [51] Industry  Possible No information provided. 
Leung [34] Industry   The flare criteria were: 40 mm and an increase of 15mm compared with screening values on question 1 of 
WOMAC questionnaire and a worsening on the investigator's global assessment of disease status by 1 point on a 
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5-point Likert scale. Pre-study paracetamol (acetaminophen) users had to demonstrate reproducible symptoms on 
the screening and randomization visits: of 40 mm pain while walking on a flat surface and patient's global 
assessment of disease status 
Lund [55] Unclear  X No information provided. 
McKenna [32] Industry   OA evidenced by a defined worsening of the signs and symptoms of the disease following discontinuation of 
treatment with NSAIDs for other analgesic medications. 
Nguyen [53] Industry  Possible No information provided. 
Nunes [22]  Unclear X X No information provided. 
Paul [17] Unclear Unclear X No information provided. 
Petersen [76] Public  Possible No information provided. 
Pincus [15] Unclear  X No information provided. 
Puopolo [40] Industry   A sufficient flare within the washout period was defined as a patient-reported pain score of at least 40 mm while 
the patient walked on a flat surface, and was at least 15 mm greater than that recorded at the pre-study visit as 
well as a worsening of at least one point (0- to 5-point Likert scale) for IGADS 
Reginster [41] Unclear   Pre-study NSAID users were required to demonstrate worsening of pain (flare) after a pre-specified washout 
period based on the half-life of the drug 
Rother [42] Industry   Patients had to meet three osteoarthritis flare criteria 
Sandelin [54] Unclear X X No information provided. 
Schmitt [57] Unclear  Possible No information provided. 
Schnitzer [47] Industry   Patient had experienced a flare of pain (Baseline WOMAC: question 1 of pain subscale value of 50 mm, with an 
increase of 15 mm compared with screening) after discontinuing all analgesic therapy at screening (for at least 5 
half-lives of the prior analgesic or anti-inflammatory therapy before the baseline visit).” 
Schnitzer [66] Industry  X No information provided. 
Schnitzer [77] Public  Possible No information provided. 
Scott [59] Unclear  Possible No information provided. 
Sheldon [69] Unclear  X No information provided. 
Shipley [50] Industry X X No information provided. 
Simon [44] Industry   Patients had to meet the osteoarthritis flare criteria 
Svensson [71] Industry X X No information provided. 
Tannenbaum [65] Industry  X No information provided. 
Truitt [18] Industry  X No information provided. 
Tuzun [70] Unclear Unclear X No information provided. 
Uzun [61] Not stated Unclear Possible No information provided. 
Wiesenhutter [37] Industry   A flare was classified as sufficient if the minimum patient-reported pain score was 40mm while the patient 
waked on a flat surface 
Williams [33] Industry   All patients included in this study experienced an OA flare at the baseline visit (day 0, within 24 hours before the 
first dose of study medication).” 
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“Patients were considered to have an OA flare if baseline scores on both the Patient’s and Physician’s Global 
Assessments of Arthritis indicated that their condition was fair, poor, or very poor. Furthermore, baseline 
assessments had to meet the following criteria: Patient’s Assessment of Arthritis Pain-VAS measurement of 240 
mm; an increase of 22 points on the Lequesne Osteoarthritis Severity Index versus values at the screening visit; 
and an increase of 21 grade on the Patient’s or Physician’s Global Assessment of Arthritis versus values at the 
screening visit.” 
“Patients with uncontrolled OA who were not receiving NSAIDs or analgesics before the study were considered 
to be experiencing an OA flare and therefore eligible for enrolment if they satisfied the following criteria: 
Patient’s Assessment of Arthritis Pain-VAS measurement of 240 mm, a Lequesne Osteoarthritis Severity Index 
score of 27, and a score on the Patient’s or Physician’s Global Assessment of Arthritis of 4 (poor) or 5 (very 
poor).” 
Wittenberg [39] Industry   Patients were required to have VAS actual pain intensity at baseline of ≥50 mm for the most severely affected 
(target) knee joint after activity. (The pain requirement at baseline following washout [≥50 mm] was greater than 
at screening [≥40 mm]; thus, an increase in pain from screening to baseline was required for study entry.) 
 - Yes; X – No; IGADS - Investigator Global Assessment of Disease Status; mm – millimetres; NSAIDs – non-steroidal anti-inflammatory drugs; OA – osteoarthritis; VAS 
– visual analogue scale; WOMAC - Western Ontario and McMaster Universities Osteoarthritis Index. 
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Supplementary Table 3: Participant characteristics of the included studies (medications and demographics) 
Study NSAIDs and Dose Duration 
of 
NSAID 
(weeks) 
Contaminant N Mean Age  Gender 
(M/F) 
Joint 
Affected 
Mean 
disease 
duration 
(years) 
Setting 
(Hospital/Community) 
Altman [21] Naproxen 500 mg BID 26 Acetaminophen 333 64 143/190 Knee Unclear Hospital 
Baerwald [45] Naproxcinod 750 mg BID 13 Acetaminophen 
 
810 63 279/531 Hip Unclear Hospital 
Naproxen 500 mg BID 
Bensen [19] Celecoxib, 50 mg BID 1 Acetaminophen, 
aspirin 
 
1003 62.2 281/722 Knee 9.8 Hospital 
Celecoxib, 100 mg BID 
Celecoxib, 200 mg BID 
Celecoxib, 500 mg BID 
Biegert [65] Diclofenac, 2 tablets BID100 
mg/day 
6 Aspirin, physical 
therapy 84 61.8 53/31 
Knee/Hip Unclear Hospital 
Bingham [38] Etoricoxib 30 mg QD 12 Acetaminophen 
 
599 62.4 195/404 Knee/Hip Unclear Unclear 
Celecoxib 200 mgQD 
Eetoricoxib 30 mg QD 12 Acetaminophen 
 
608 61.8 209/399 Knee/Hip Unclear Unclear 
Celecoxib 200 mg QD 
Bocanegra [28] Diclofenac sodium 75 mg 
BID 
6  Unclear 572 62.5 180/392 Knee/Hip 11.2 Hospital 
Diclofenac/misoprostol 
D50/M200 TID 
Diclofenac/misoprostol 
D75/M200 BID 
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Bourgeois [16] Nimesulide 50 mg  BID 4 Paracetamol 
382 u Unclear 
Knee Unclear Unclear 
Nimesulide 100 mg BID 
Nimesulide 200 mg BID 
Case [63] Diclofenac sodium 75 mg 
BID 
12 Unclear 
82 62.2 41/41 
Knee Unclear Hospital 
Cryer [46] Naproxen/esomeprazel 
magnesium tablets BID  
12 Prednisone, 
antiplatelet agents 
, antacid, 
acetaminophen 
 
612 61.6 221/391 Knee Unclear Hospital 
Celecoxib 200mg capsules 
QD 
Davies [56] Ibuprofen 800 mg TID 4 Acetaminophen 
104 61.5 38/66 
Knee/Hip/ 
Spine 
7.9 Hospital 
Day [30] Rofecoxib 12.5 mg QD 6 Acetaminophen 
 
809 63.6 162/647 Knee/Hip 8.7 Hospital 
Rofecoxib 25 mg QD 
Ibuprofen 800 mg TID 
DeLemos [75] Celecoxib 200 mg QD 12 Aspirin, 
acetaminophen 
1001 58 369/632 
Knee/Hip 8.1 Hospital 
Dickson [60] Diclofenac 100mg/day, 3 
weekly arthrocenteses 
3 Acetaminophen 
165 64.5 73/92 
Knee Unclear Community 
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Ding [74] Ibuprofen, 0.3g, BID 2 Health education 90 56 25/65 Knee 4.7 Hospital 
Dougados [72] Lumiracoxib 100 mg QD 13 Sheldon 2005: 
acetaminophen 
3235 61.5 1097/2138 
Knee 5.5 Unclear 
Lumiracoxib 100 mg QDwith 
initial dose 
Celecoxib 200 mg QD 
Dreiser [52] Ibuprofen 800 mg QD 2 Unclear 60 59.4 9/51 Hand Unclear Hospital 
Ehrich [31] Rofecoxib 5 mg QD 6 None 672 61.7 195/477 Knee/Hip 10.9 Unclear 
Rofecoxib 12.5 mg QD 
Rofecoxib 25 mg QD 
Rofecoxib 50 mg QD 
Ehrich [29]  Rofecoxib 25 mg QD 6 Acetaminophen 219 63.5 63/156 Knee 11.9 Hospital 
Rofecoxib 125 mg QD 
El-Mehairy [49] Nifiumic acid 250 mg TID 8 Unclear 
100 54.6 14/86 
Knee/Hip Unclear Hospital 
Phenylbutazone (100 
mg/capsule), NSAIDs, TID 
Oxyphenylbutazon 100 mg, 
NSAIDs, TID 
Essex [48] Celecoxib 200 mg QD 6 Aspirin, 
acetaminophen 
 
322 58 64/258 Knee 5.4 Hospital 
Naproxen 500 mg BID Knee/Hip 
Fleischmann 
[36] 
Lumiracoxib 200 mg oQD 13 Paracetamol 
 
1600 61.1 539/1061 Knee 6.4 Hospital 
Lumiracoxib 400 mg QD 
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Celecoxib 200 mg QD 
Gibofsky [64] Celecoxib 200 mg/day 6 Aspirin, 
acetaminophen 
477 62.9 157/320 
Knee 8.6 Unclear 
Rofecoxib 25 mg/day 
Goldstein [58] Naproxen 375 mg daily week 
1, week 2-3: naproxen 375 
mg BID 
3 Acetaminophen 
194 61.2 72/122 
Knee/Hip Unclear Hospital 
Grifka [35] Lumiracoxib 200 mg QD 4 Paracetamol 
 
594 61.9 104/490 Hand 5.3 Hospital 
Lumiracoxib 400 mg QD 
Haghighi [68] Ibuprofen three 400 mg 
tablets daily 
4 Acetaminophen 
120 56.8 89/31 
Knee/Hip Unclear Hospital 
Karlsson [43] Naproxcinod 750mg QD 6 Paracetamol, 
antihypertensive 
drugs 
543 61.5 177/366 Knee/Hip Unclear Hospital 
Naproxcinod 750mg BID 
Naproxcinod 1125mg BID 
Rofecoxib 25 mg QD 
Kivitz [62] Valdecoxib 5 mg QD 12 Unclear 
1015 59.7 356/659 
Knee 9.1 Community 
Valdecoxib 10 mg QD 
Valdecoxib 20 mg QD 
Naproxen 500 mg BID 
Kruger [73] Oxaceprol 200 mg TID 3 Acetaminophen 97 59.6 31/66 Knee/Hip Unclear Hospital 
Lee [51] Diflunisal 500 mg BID 6 None 
422 61.3 139/283 
Knee 5 Unclear 
Diflunisal 375 mg BID 
Leung [34] Etoricoxib 60 mg QD 12 Paracetamol 501 63.2 109/392 Knee/Hip 6.1 Hospital 
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Naproxen 500 mg BID  
Lund [55] Meloxicam 7.5 mg 3 Paracetamol, 
message, exercise 411 68.5 112/299 
Knee Unclear Hospital 
McKenna [32] Celecoxib 100 mg BID 6 Aspirin 
 
600 61.7 208/392 
 
Knee 8.6 Unclear 
Diclofenac 50 mg TID 
Nguyen [53] Tenoxicam 20 mg QD 8 Paracetamol 145 62.6 62/83 Hip 5.6 Hospital 
Nunes [22] Alginac TIDvitamin b12, b6, 
b1 
2 Unclear 
80 42.1 42/38 
Knee/Hip 2.2 Unclear 
Paul [17] Aceclofenac (100 mg) BID 4 Paracetamol 
423 53.5 188/235 
Knee 4.3 Hospital 
Nabumetone (750 mg) BID 
Petersen [76] Ibuprofen 600mg BID 12 Quadriceps 
muscle strength, 
acupuncture 35 62.4 14/21 
Knee Unclear Hospital 
Pincus [15] Celecoxib 200 mg/day 6 Propoxyphene; 
codeine 60 mg or 
tramadol rescue 
medication 524 U Unclear 
Knee/Hip Unclear Unclear 
Puopolo [40] Etoricoxib 30 mg QD 12 Acetaminophen 
 
816 62.6 198/618 Knee/Hip 6.6 Hospital 
Ibuprofen 800 mg TID 
Reginster [41] Etoricoxib 60 mg QD 
Naproxen 500 mg BID 
12 Paracetamol 
 
997 62.8 279/718 Knee/Hip Unclear Unclear 
Rother [42] Celecoxib 100 mg oral and 
placebo gel 
6 Paracetamol 
 
397 62.8 160/237 Knee Unclear Hospital 
Sandelin [54] Diclofenac 50 mg BID 4 None 281 61 92/189 Knee Unclear Hospital 
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Schmitt [57] Diclofenac sodium 150 mg 
dual release capsules 
(DRC150) QD 
12 None 
393 60.9 63/330 
Knee/Hip 8.8 Hospital 
Diclofenac sodium 75 mg QD 
Voltaren 50 mg enteric coated 
tablet (EC50) TID 
Schnitzer [47] Naproxcinod 750 mg BID  13 Acetaminophen 
 
1000 59.8 291/709 Knee Unclear Unclear 
Naproxcinod 375 mg BID 
Naproxcinod 500 mg BID 
Schnitzer [66] Lumiracoxib 50 mg BID 4 Acetaminophen 
583 60.3 187/396 
Knee/Hip 6.9 Unclear 
Lumiracoxib 100 mg BID 
Lumiracoxib 200 mg BID 
Lumiracoxib 400 mg BID 
Schnitzer [77] Lumiracoxib 100 mg QD 13 Acetaminophen 
1262 61.6 485/777 
Hip Unclear Unclear 
Celecoxib 200 mg QD 
Scott [59] Tiaprofenic acid 300 mg BID 4 Acetaminophen 
812 61 240/572 
Knee 5 Unclear 
Indomethacin 25 mg TID 
Sheldon [69] Lumiracoxib 100 mg QD 13 Acetaminophen 1551 60.5 583/968 Knee 6.9 Hospital 
Shipley [50] Fenoprofen 600 mg TID 2 Paracetamol; 
homeopathy 
therapy 33 65 9/24 
Knee/Hip Unclear Hospital 
Rhus tox 
Simon [44] oral diclofenac tablets 100 mg 12 glucosamine, 
chondroitin, 
paracetamol 
772 61.6 289/483 Knee Unclear Hospital 
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Svensson [71] 
 
Naproxen 500 mg BID 8 Unclear 511 59.7 151/360 Knee Unclear Unclear 
Naproxen 500 mg BID 8 Unclear 511 59.7 151/360 Hip Unclear Unclear 
Tannenbaum 
[67] 
Lumiracoxib 200 mg, QD 13 Paracetamol 
1702 64.2 536/1166 
Knee 4.8 Unclear 
Lumiracoxib 400 mg, QD 
Celecoxib 200 mg, QD 
Truitt [18] Rofecoxib 12.5 mg QD 6 Acetaminophen 
341 83 124/217 
Knee/Hip 15 Hospital 
Rofecoxib 25 mg QD 
Nabumetone 1500 mg QD 
Tuzun [70] 
Flurbiprofen 100 mg PO 
(tablets) BID 
3 Unclear 
39 59.1 19/20 
Knee 5.1 Hospital 
Tiaprofenic acid 300 mg PO 
(tablets) BID 
Uzun [61] Flurbiprofen  100 mg BID 3 Unclear 
39 59.1 20/19 
Knee 5.1 Hospital 
Tiaprofenic acid 300 mg BID 
Wiesenhutter 
[37] 
Etoricoxib 30 mg/d 12 Acetaminophen, 
aspirin, stable 
glucosamine or 
chondroitin 
 
528 61.5 156/372 Knee/Hip 7.8 Unclear 
Ibuprofen 2400mg/d 
Williams [33] Celecoxib 100 mg BID 6 Aspirin, 
acetaminophen 
718 61.5 214/504 Knee Unclear Unclear 
Celecoxib 200 mg QD 
Wittenberg [39] Lumiracoxib 400 mg QD 1 Acetaminophen 
 
334 65 123/211 Knee 7.5 Unclear 
Celecoxib 200 mg BID 
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BID – twice a day; F – female; M- Male; mg – milligrams; mg/d – milligrams per day;  N – number of participants; PO – orally taken; QD – once a day; TID – three times a 
day 
 
Supplementary Table 4: Summary of the included trial quality assessment results 
Study Randomisation 
Defined 
Allocation 
concealment 
Blinding of 
participants 
Blinding of 
clinicians 
Blinding of 
assessors 
Follow-
up >85% 
ITT 
Analysis 
Performed 
Altman [21] Unclear Unclear  X  X Unclear 
Baerwald [45] Unclear Unclear  Unclear Unclear X  
Bensen [19]  Unclear    X  
Biegert [65]  Unclear  Unclear  X  
Bingham [38] Unclear Unclear  Unclear Unclear X  
Bocanegra [28] Unclear Unclear  Unclear Unclear X  
Bourgeois [16]  Unclear    X X 
Case [63] Unclear Unclear  Unclear Unclear X  
Cryer [46]        
Davies [56] Unclear Unclear  Unclear Unclear  X 
Day [30]       X 
DeLemos [75] Unclear Unclear  Unclear Unclear X  
Dickson [60] Unclear Unclear  X  X  
Ding [74]   X X X   
Dougados [72] Unclear Unclear  Unclear Unclear X  
Dreiser [52] Unclear Unclear  Unclear Unclear   
Ehrich [29]      X  
Ehrich [31] Unclear Unclear  Unclear Unclear X  
El-Mehairy [49] Unclear Unclear      
Essex [48]  Unclear  Unclear Unclear X  
Fleischmann [36] Unclear Unclear   Unclear X  
Gibofsky [64]      X  
Goldstein [58] Unclear Unclear  Unclear Unclear  X 
Grifka [35] Unclear Unclear  Unclear Unclear   
Haghighi [68] Unclear Unclear  Unclear Unclear   
Karlsson [43]      X  
Kivitz [62]      X  
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Kruger [73]      X  
Lee [51] Unclear Unclear  Unclear Unclear X X 
Leung [34]     Unclear X X 
Lund [55] Unclear Unclear  Unclear Unclear   
McKenna [32] Unclear Unclear  Unclear Unclear X  
Nguyen [53]  Unclear      
Nunes [22]  Unclear Unclear  Unclear Unclear  Unclear 
Paul [17] Unclear Unclear    X X 
Petersen [76]       X 
Pincus [15] Unclear Unclear  Unclear Unclear X  
Puopolo [40]      X  
Reginster [41]    Unclear Unclear X X 
Rother [42]     Unclear X  
Sandelin [54]    Unclear Unclear   
Schmitt [57] Unclear Unclear  Unclear Unclear X  
Schnitzer [47] Unclear Unclear    X  
Schnitzer [66] Unclear Unclear  Unclear Unclear   
Schnitzer [77]  Unclear    X  
Scott [59] Unclear Unclear  X X Unclear Unclear 
Sheldon [69] Unclear Unclear  Unclear Unclear X  
Shipley [50] Unclear Unclear   Unclear  X 
Simon [44]      X  
Svensson [69] Unclear Unclear  Unclear Unclear Unclear Unclear 
Tannenbaum [65] Unclear Unclear  Unclear Unclear X  
Truitt [18]      X  
Tuzun [70] Unclear Unclear X X X Unclear Unclear 
Uzun [61] Unclear Unclear Unclear Unclear Unclear Unclear Unclear 
Wiesenhutter [37] Unclear Unclear   Unclear X  
Williams [33] Unclear Unclear    X  
Wittenberg [39] Unclear Unclear   Unclear   
  - satisfied; X – not satisfied; ITT – intention-to-treat analysis 
 
 
